Hypertonic saline monotherapy in children with perennial allergic rhinitis: a pilot study

Area of Science:

• Pediatric Allergy and Immunology
• Otolaryngology
• Nasal Therapeutics

Background:

• Perennial allergic rhinitis (PAR) significantly impacts children's quality of life and family well-being.
• House dust mites (HDM) are a primary trigger for PAR in pediatric populations.
• Effective and safe monotherapy options for pediatric PAR require further investigation.

Purpose of the Study:

• To assess the efficacy of 3% hypertonic saline nasal spray as monotherapy for pediatric PAR.
• To evaluate improvements in nasal symptom severity and parental perception of rhinitis control.
• To determine the impact on children's sleep and school performance.

Main Methods:

• Pilot study involving 25 children (mean age 9.5 years) with HDM-sensitized PAR.
• Treatment with 3% hypertonic saline nasal spray for 3 weeks.
• Assessments at baseline, end of treatment, and 2-week follow-up.

Main Results:

• Significant reduction in total nasal symptom scores.
• Improved parental perception of rhinitis control.
• Enhanced sleep quality and school performance reported by parents.

Conclusions:

• 3% hypertonic saline monotherapy demonstrates efficacy in relieving nasal symptoms in children with PAR.
• The treatment positively influences parental perception of rhinitis control, sleep, and school performance.
• Hypertonic saline nasal spray is a safe and well-tolerated option for pediatric PAR.